Global Genomics Group (G3) Announces Completion of Enrollment in GLOBAL Study with 7,500 Patients

RICHMOND, Va., May 27, 2014 /PRNewswire/ -- Global Genomics Group (G3), a life sciences company investigating biological networks that lead to the development of disease, today announced that it has completed the enrollment of patients in its international, prospective GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) study, months ahead of schedule. GLOBAL is the first pan-omic study designed to identify disease-related pathways, new drug targets and biomarkers for cardiovascular diseases such as atherosclerosis.

"The early completion of the GLOBAL study is a significant milestone for G3 and confirms the strong support and interest from the medical community," said Tonya Mallory, chief executive officer, president and co-founder of Health Diagnostic Laboratory, a strategic partner of G3. "G3 is in the process of analyzing the initial data and could have pilot data results as early as the first half of 2015. The study will analyze 22 trillion data points from 7,500 patients and will enable us to gain an in-depth understanding of the biological basis behind the complex processes responsible for atherosclerosis, leading to the identification of new biomarkers for early detection and new targets for the development of novel and effective drugs. As of today, only 20 drug candidates are being developed for atherosclerosis and coronary artery disease, the leading cause of death worldwide."

John Lesser, M.D., one of the principal investigators for the GLOBAL study and former president of the Society of Cardiovascular Computed Tomography, said, "Early disease detection and intervention, as well as effective therapeutic options, remain significant unmet medical needs in cardiovascular disease.  It is quite remarkable to see such a large scale, comprehensive study executed so quickly. I am thrilled to be a part of this work, and I am looking forward to the potential of using the clinical diagnostic tests that result."

The GLOBAL study completed the enrollment of 7,500 patients at 48 clinical sites in North America, Europe, and Australia. For more information about this study, please visit www.globalgenomicsgroup.com.

About GLOBAL

GLOBAL is the largest pan-omic study combining whole genome sequencing, whole genome methylation, whole transcriptome sequencing, unbiased proteomics, metabolomics and lipidomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping, which allows the precise classification of disease in patients.

The ongoing GLOBAL study (ClincialTrials.gov Identifier NCT01738828) is an international, prospective, multi-center study recruiting up to 10,000 patients to characterize novel disease networks and biomarkers for coronary artery disease (CAD). The study is being funded by G3 and conducted together with strategic partner, Health Diagnostic Laboratory. Eligible patients undergo coronary CT angiography providing an accurate and detailed examination of the disease and disease status. This precision phenotyping is combined with a pan-omic analysis, and the data is then analyzed utilizing specifically-developed systems biology-based bioinformatics technology for identification of diagnostic biomarkers and potential therapeutic targets.

About Global Genomics Group (G3)
G3 is a life sciences company investigating biological networks that lead to the development of disease to identify novel biomarkers and therapeutic targets. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics) and bioinformatics to investigate the development and progression of conditions such as atherosclerosis in cardiovascular disease.

For additional information, please visit www.globalgenomicsgroup.com.

G3 Contacts
Media
Martina Schwarzkopf, Ph.D.
(212) 845-4292
[email protected]

Corporate
Idean Marvasty
(404) 368-1554
[email protected]

SOURCE Global Genomics Group (G3)